Drug comparison · Anticonvulsants

Topamax vs Depakote

A clinical comparison of topiramate and valproate — two anticonvulsants used for epilepsy and migraine prevention with dramatically different effects on weight, cognition, and pregnancy safety.

Topamax

Topamax

topiramate

Anticonvulsant Carbonic anhydrase inhibitor Weight loss "Dopamax"
Depakote

Depakote

valproate / valproic acid

Anticonvulsant Mood stabilizer Major teratogen Weight gain

Side-by-side

Comparison table

Feature Topamax (topiramate) Depakote (valproate)
Drug class Anticonvulsant; carbonic anhydrase inhibitor Anticonvulsant / mood stabilizer
Mechanism Blocks voltage-gated Na⁺/Ca²⁺ channels; potentiates GABA-A; blocks AMPA/kainate receptors; inhibits carbonic anhydrase (CA-II, CA-IV) Increases brain GABA; blocks voltage-gated Na⁺/Ca²⁺ channels; inhibits histone deacetylases
Weight effect Weight loss — appetite suppression; used in Qsymia Significant gain — increased appetite, metabolic effects
Cognition "Dopamax" — word-finding difficulty, slowed thinking Sedation, fatigue, tremor
Teratogenicity Moderate risk — cleft palate/lip; avoid in pregnancy Major teratogen — Black Box; neural tube defects, fetal valproate syndrome
Bipolar use Not FDA-approved — off-label data limited FDA-approved — acute manic & mixed episodes
Migraine prevention Yes — FDA approved Yes — FDA approved (Depakote ER)
Weight loss use Yes — Qsymia component; off-label for obesity/binge eating No
Kidney stones Increased risk — carbonic anhydrase inhibition Not reported
Hepatotoxicity Not prominent Yes — especially young children; Black Box
Hair loss Not typical Common
Tremor Uncommon Common — dose-related
Sedation Mild Moderate
Metabolic acidosis Yes — carbonic anhydrase inhibition lowers serum bicarbonate Not prominent
Oligohidrosis Rare but reported — reduced sweating, overheating risk Not reported
Blood monitoring Serum bicarbonate; kidney function periodically Valproate levels + LFTs + CBC required regularly
Drug interactions Moderate — OCPs: minor reduction; carbonic anhydrase inhibitors: additive stone risk Extensive — inhibits CYP enzymes; doubles lamotrigine levels
Generic available Yes Yes
Pancreatitis risk Not reported Rare but reported

FDA-approved uses

Approved indications

Topamax (topiramate)

  • Epilepsy — initial monotherapy for partial-onset or primary generalized tonic-clonic seizures (adults & children ≥10 yr)
  • Epilepsy — adjunctive therapy for partial-onset seizures, primary generalized tonic-clonic seizures, and Lennox-Gastaut syndrome (adults & children ≥2 yr)
  • Migraine prevention in adults and adolescents ≥12 yr
  • Weight management (as Qsymia, combined with phentermine) — chronic weight management in adults with BMI ≥30, or ≥27 with a weight-related condition

Off-label: obesity (topiramate alone), binge eating disorder

Depakote (valproate)

  • Epilepsy — complex partial seizures (monotherapy & adjunctive, adults & children ≥10 yr)
  • Epilepsy — simple and complex absence seizures; adjunctive for multiple seizure types including absence
  • Bipolar disorder — acute manic or mixed episodes (adults)
  • Migraine prevention — Depakote ER in adults

⚠ Contraindicated in pregnancy for migraine; avoid in women of childbearing potential without effective contraception and awareness of teratogenic risk

Formulations

Available strengths

Topamax (topiramate)

Tablets & capsules

Tablets
25 mg 50 mg 100 mg 200 mg
Sprinkle capsules (Topamax Sprinkle)
15 mg 25 mg
Extended-release capsules (Trokendi XR / Qudexy XR)
25 mg 50 mg 100 mg 150 mg 200 mg

Depakote (valproate)

Multiple formulations

Depakote delayed-release tablets
125 mg 250 mg 500 mg
Depakote ER (extended-release tablets)
250 mg 500 mg
Depakote Sprinkle capsules
125 mg
Depakene (valproic acid capsules)
250 mg
Depakene syrup (valproic acid oral solution)
250 mg/5 mL

What sets them apart

Key clinical differences

⚖️
Weight: opposite directions

Topiramate (Topamax) is one of very few anticonvulsants that causes weight loss — appetite suppression is strong enough that it is a component of the FDA-approved weight-loss drug Qsymia. Valproate (Depakote) causes significant weight gain, one of the most common reasons patients discontinue it. This difference is a major factor in prescribing decisions, especially for patients with obesity, binge eating, or concerns about metabolic health.

🧠
Cognition: "Dopamax" vs sedation

Topiramate has a well-known and distinctive cognitive side effect: word-finding difficulty, slowed processing, and verbal fluency problems — nicknamed "Dopamax" by patients. These effects are real, dose-related, and affect up to 25–30% of users at therapeutic doses. Valproate more typically causes sedation, fatigue, and tremor. Patients on topiramate who notice it is affecting their thinking should discuss dose adjustments with their prescriber.

🧬
Topiramate: carbonic anhydrase inhibitor

Topiramate's inhibition of carbonic anhydrase (CA-II and CA-IV) is responsible for several unique side effects not seen with valproate: increased risk of kidney stones (calcium phosphate stones), metabolic acidosis (lowered serum bicarbonate), and, rarely, oligohidrosis (reduced sweating) that can cause dangerous overheating especially in children. Patients should stay well hydrated and avoid other carbonic anhydrase inhibitors (e.g., acetazolamide, zonisamide) unless their prescriber is aware.

💊
Depakote: broad spectrum + bipolar mania

Valproate has broader anticonvulsant coverage — it is effective for absence seizures, myoclonic seizures, and complex partial seizures, while topiramate does not have the same profile for generalized absence. Valproate is also FDA-approved for bipolar mania, making it useful for patients with both epilepsy and bipolar disorder. Topiramate is not FDA-approved for bipolar disorder, and evidence for its use in that context is limited.

Safety

Warnings & pregnancy risk

Black Box Warning — Depakote (valproate)

Major teratogen: neural tube defects & fetal valproate syndrome

Valproate carries an FDA Black Box Warning for teratogenicity. Exposure during the first trimester increases the risk of neural tube defects (including spina bifida) by approximately 1–2%. Children exposed in utero also face risk of fetal valproate syndrome — characteristic facial features, limb abnormalities — and significantly lower IQ scores. Additional Black Box Warnings cover serious hepatotoxicity (especially in children under 2 years old and those on polytherapy) and pancreatitis.

  • Contraindicated for migraine prevention in pregnancy
  • Should not be used in women of childbearing potential for epilepsy or bipolar disorder unless other medications are inadequate
  • Requires enrollment in the NAAED Pregnancy Registry if used during pregnancy
  • Requires regular monitoring of valproate blood levels, liver function tests, and CBC

Pregnancy Warning — Topamax (topiramate)

Increased risk of cleft palate and cleft lip

Topiramate is associated with an increased risk of oral clefts (cleft palate and cleft lip) in infants exposed in utero — estimated at approximately 1.4% vs 0.07% in unexposed infants (a roughly 20-fold increase in relative risk, though absolute risk remains low). While this risk is considerably lower than valproate's risk of neural tube defects, topiramate should be avoided in pregnancy when alternatives exist. Women of childbearing potential should use effective contraception and discuss risks with their prescriber. Topiramate may also reduce the effectiveness of some hormonal contraceptives at higher doses.

Common questions

Frequently asked questions

Does Topamax cause weight loss and Depakote cause weight gain?
Yes — weight change is one of the most clinically significant differences between the two drugs. Topiramate (Topamax) is unusual among anticonvulsants in that it consistently causes weight loss, likely through appetite suppression and reduced caloric intake. This effect is strong enough that topiramate is approved as a weight-loss medication (as part of the combination drug Qsymia) and is used off-label for obesity and binge eating disorder. Valproate (Depakote), by contrast, is associated with substantial weight gain — one of the most common reasons patients discontinue it. The mechanism is thought to involve increased appetite, effects on insulin sensitivity, and possible interference with fatty acid metabolism.
Which is safer in pregnancy — Topamax or Depakote?
Both drugs carry pregnancy warnings, but valproate (Depakote) is far more dangerous to a developing fetus. Depakote carries an FDA Black Box Warning for teratogenicity: it is associated with a 1–2% risk of neural tube defects (including spina bifida), as well as fetal valproate syndrome. Topiramate (Topamax) also carries pregnancy warnings — specifically an increased risk of cleft palate and cleft lip in exposed infants — but this risk is considerably lower than valproate's. Neither drug should be used in pregnancy without a careful discussion with a physician. Women of childbearing potential taking either drug should use effective contraception.
What is "Dopamax" and why does Topamax affect thinking?
"Dopamax" is a patient nickname for topiramate (Topamax) that refers to its well-documented cognitive side effects, particularly word-finding difficulty (anomia), slowed thinking, and impaired verbal fluency. These effects are real, common (reported by up to 25–30% of patients at therapeutic doses), and dose-related — they tend to be worse at higher doses and may improve with dose reduction. The mechanism is not fully understood but may relate to topiramate's inhibition of carbonic anhydrase and its effects on glutamate receptors. Valproate (Depakote) also causes CNS side effects, but more commonly sedation, fatigue, and tremor rather than word-finding problems specifically.
Can Topamax be used for weight loss or binge eating?
Yes. Topiramate is FDA-approved as part of the combination drug Qsymia (topiramate extended-release + phentermine) for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It is also used off-label alone for obesity and has evidence in clinical trials for binge eating disorder. The weight-loss effect is among the strongest seen with any pharmaceutical agent outside the GLP-1 receptor agonist class. Valproate (Depakote) is not used for weight management and typically causes weight gain.
Does Depakote require blood level monitoring?
Yes. Valproate (Depakote) requires regular blood level monitoring for several reasons. Valproic acid levels are drawn to ensure therapeutic concentrations and to avoid toxicity. Liver function tests (LFTs) are required because valproate carries a risk of serious hepatotoxicity. A complete blood count (CBC) is also monitored because valproate can cause thrombocytopenia (low platelets). Topiramate (Topamax) does not require routine blood level monitoring in the same way, though kidney function and serum bicarbonate may be checked periodically because topiramate is a carbonic anhydrase inhibitor and increases the risk of kidney stones and metabolic acidosis.
Can both Topamax and Depakote be used for migraine prevention?
Yes, both are FDA-approved for migraine prevention in adults. Topiramate (Topamax) is approved for migraine prophylaxis and is often preferred in patients concerned about weight, since it causes weight loss rather than gain. Valproate (Depakote ER) is also approved for migraine prevention, but its use is contraindicated in pregnancy and should be avoided in women of childbearing potential without adequate contraception, due to its severe teratogenic risk. The choice between them for migraine prevention often comes down to weight concerns, pregnancy risk, and individual tolerability.
Does Depakote cause hair loss?
Yes. Hair loss (alopecia) is a recognized and relatively common side effect of valproate (Depakote). It typically presents as diffuse thinning rather than focal loss and is often dose-related. Some patients find that supplementing with zinc and selenium helps, though evidence is limited. Hair loss may improve with dose reduction. Topiramate (Topamax) is not typically associated with significant hair loss, though it has its own distinct side-effect profile including the cognitive effects described by "Dopamax."
What is topiramate's mechanism of action?
Topiramate (Topamax) works through multiple mechanisms: it blocks voltage-gated sodium channels, inhibits certain voltage-gated calcium channels, potentiates GABA-A receptor activity, blocks AMPA/kainate glutamate receptors, and inhibits carbonic anhydrase (CA-II and CA-IV). The carbonic anhydrase inhibition is responsible for several distinctive side effects, including the risk of kidney stones, metabolic acidosis, and reduced sweating (oligohidrosis). Valproate (Depakote) also works through multiple mechanisms, including increasing brain GABA levels, blocking voltage-gated sodium and calcium channels, and inhibiting histone deacetylases.

More comparisons

💊Lamictal vs Depakote 💊Gabapentin vs Lyrica 💊Ambien vs Lunesta 💊Xanax vs Klonopin 💊Seroquel vs Abilify